Skip to main navigation Skip to search Skip to main content

A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone In Participants with Advanced Nonsmall Cell Lung Cancer Who have Progressed on prior Anti-P -(L)1 Therapy

Project: Research

Project Details

StatusActive
Effective start/end date01/20/22 → 07/1/26

Funding

  • PPD Investigator Services LLC: $21,025.00